Yingxiang Lv

Shenyang Pharmaceutical University, Feng-t’ien, Liaoning, China

Are you Yingxiang Lv?

Claim your profile

Publications (1)3.45 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: A series of novel 4-thiazolidinone and indolin-2-one hybrid derivatives 5a-5s and 10a-10s have been designed and synthesized and their cytotoxic activities were evaluated in vitro against three human cancer cell lines including HT-29 (human colon cancer), H460 (human lung cancer), MDA-MB-231 (human breast cancer) by MTT assay. Several potent target compounds (5m, 5p, 5s, 10a, 10c-10g, 10m, 10p) were further evaluated against one cancer cell line SMMC-7721 (human liver cancer) and one normal cell line WI-38 (human fetal lung fibroblasts). Most of the prepared compounds exhibited significant antitumor activities against different human cancer cell lines. Compound 10c (IC(50) = 0.025 μM, 0.075 μM, 0.77 μM, 1.95 μM) was 52, 36, 4.8 and 3.3 times more active than Sunitinib (IC(50) = 1.3 μM, 2.7 μM, 3.7 μM, 6.47 μM) against HT-29, H460, MDA-MB-231 and SMMC-7721 cancer cell line, respectively.
    European Journal of Medicinal Chemistry 08/2011; 46(8):3509-18. DOI:10.1016/j.ejmech.2011.05.017 · 3.45 Impact Factor

Publication Stats

32 Citations
3.45 Total Impact Points


  • 2011
    • Shenyang Pharmaceutical University
      • School of Pharmaceutical Engineering
      Feng-t’ien, Liaoning, China